Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: A cohort study
Rheumatology International Oct 19, 2017
Kume K, et al. - A cohort study is carried out to examine the impacts of Tofacitinib treatment, a Janus kinase inhibitor, on atherosclerosis in patients with rheumatoid arthritis (RA). The current study showed that the Tofacitinib decreased RA disease activity and limited vascular damage despite up-regulating cholesterol in patients with an active RA.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
